Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AQST 4.46 +0.15(3.48%)
Will AQST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AQST
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 16th
New Strong Sell Stocks for July 11th
5 Small Drug Stocks to Buy From a Recovering Industry
Other News for AQST
Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm?
Aquestive Therapeutics reiterates expected timing for NDA filing of Anaphylm